Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shereen Ezzat

Showing results (71-80 of 249) with videos related to

Pageof 25
Sort By:
Endocrine Pathology|October 6, 2007
AIP Mutations are not identified in patients with sporadic pituitary adenomasRebecca DiGiovanni, Stefano Serra, Shereen Ezzat, et al.
Molecular and Cellular Endocrinology|January 12, 2010
Chromatin remodeling and histone modifications in pituitary tumorsToru Tateno, Xuegong Zhu, Sylvia L Asa, et al.
BMC Public Health|September 10, 2016
A detailed spatial analysis on contrasting cancer incidence patterns in thyroid and lung cancer in Toronto womenPatrick Brown, Hedy Jiang, Shereen Ezzat, et al.
Molecular Endocrinology (Baltimore, Md.)|July 22, 2006
Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implicationsShereen Ezzat, Lei Zheng, Daniel Winer, et al.
Endocrine Pathology|November 26, 2002
Is granulomatous thyroiditis a complication of breast implants?Ally P H Prebtani, Sylvia L Asa, Shereen Ezzat
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancerTetsuo Kondo, Xuegong Zhu, Sylvia L Asa, et al.
American Journal of Physiology. Endocrinology and Metabolism|August 10, 2002
Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoterShunjiang Yu, Lei Zheng, Sylvia L Asa, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|September 26, 2006
Dopaminergic resistant prolactinomas in the peripubertal populationCarol Huang, Shereen Ezzat, Sylvia L Asa, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 18, 2010
Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative actionWei Liu, Miao Guo, Shereen Ezzat, et al.
The American Journal of Pathology|November 2, 2010
Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancerXuegong Zhu, Lei Zheng, Sylvia L Asa, et al.
Pageof 25

Showing results (71-80 of 249) with videos related to

Sort By:
Pageof 25
Endocrine Pathology|October 6, 2007
AIP Mutations are not identified in patients with sporadic pituitary adenomasRebecca DiGiovanni, Stefano Serra, Shereen Ezzat, et al.
Molecular and Cellular Endocrinology|January 12, 2010
Chromatin remodeling and histone modifications in pituitary tumorsToru Tateno, Xuegong Zhu, Sylvia L Asa, et al.
BMC Public Health|September 10, 2016
A detailed spatial analysis on contrasting cancer incidence patterns in thyroid and lung cancer in Toronto womenPatrick Brown, Hedy Jiang, Shereen Ezzat, et al.
Molecular Endocrinology (Baltimore, Md.)|July 22, 2006
Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implicationsShereen Ezzat, Lei Zheng, Daniel Winer, et al.
Endocrine Pathology|November 26, 2002
Is granulomatous thyroiditis a complication of breast implants?Ally P H Prebtani, Sylvia L Asa, Shereen Ezzat
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancerTetsuo Kondo, Xuegong Zhu, Sylvia L Asa, et al.
American Journal of Physiology. Endocrinology and Metabolism|August 10, 2002
Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoterShunjiang Yu, Lei Zheng, Sylvia L Asa, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|September 26, 2006
Dopaminergic resistant prolactinomas in the peripubertal populationCarol Huang, Shereen Ezzat, Sylvia L Asa, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 18, 2010
Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative actionWei Liu, Miao Guo, Shereen Ezzat, et al.
The American Journal of Pathology|November 2, 2010
Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancerXuegong Zhu, Lei Zheng, Sylvia L Asa, et al.
Pageof 25